Impact of Tyrosine Kinase Inhibitors and Co-medications on the Efficacy of Patients with Advanced Non-small Cell Lung Cancer
碩士 === 國立陽明大學 === 藥理學研究所 === 106 === Tyrosine kinase inhibitors (TKIs) including gefitinib, erlotinib, afatinib and osimertinib are recommended as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-activating mutations....
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2018
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/39dv28 |